Sanofi’s waiting period to complete the purchase of Bioverativ has came to an end, and will thus expand its hemophilia and other rare blood disorders to its portfolio.
The French drugmaker’s CEO Olivier Brandicourt said in the announcement from January, this will enable Sanofi to build on Bioverativ’s success in driving new standards of care with its extended half-life factor replacement therapies. “Combined, we will continue to leverage our scientific know-how, disciplined focus and development expertise that best position us to drive value for our shareholders and create breakthrough treatments for patients,” Brandicourt said.
On February 7, 2018, Sanofi begun a tender offer to buy all outstanding shares of common stock of Bioverativ for $105 per share in cash, without interest thereon and net of any required tax withholding.
The finishing still depends on certain customary conditions described in the offer, filed by Sanofi with the U.S. Securities and Exchange Commission.
Image: A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann/File Photo